Fate Therapeutics
FATE
53 hedge funds and large institutions have $114M invested in Fate Therapeutics in 2017 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 4 closing their positions.
500% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
97% more capital invested
Capital invested by funds: $57.9M → $114M (+$56M)
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
43% more funds holding
Funds holding: 37 → 53 (+16)
7.26% less ownership
Funds ownership: 67.73% → 60.47% (-7.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.28M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.92M |
| 3 |
6CM
683 Capital Management
New York
|
+$1.72M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$928K |
| 5 |
Millennium Management
New York
|
+$717K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$6.64M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$3.31M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$122K |
| 4 |
PA
Parallel Advisors
San Francisco,
California
|
-$63K |
| 5 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$48.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | – | – | – |
|
|
PA
52
Parallel Advisors
San Francisco,
California
| – | -$63K | -25,000 | Closed |
|
|
HCIA
53
Hochman Cole Investment Advisors
Deerfield,
Illinois
| – | -$27K | -10,887 | Closed |
|
54
UBS Group
Zurich,
Switzerland
| – | -$2K | -738 | Closed |
|
55
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$22 | +6 | New |
|
56
Citigroup
New York
| – | +$366 | +100 | New |
|
FATE Hedge Fund Activity: Q1 2017 in Review
53 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2017, worth a combined $114M — up 97% from $57.9M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new FATE positions and 4 closed out — a net gain of 20 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $9.28M. The largest seller was BVF Inc, cutting an estimated $6.64M.
- 53 institutional investors held Fate Therapeutics (FATE) as of Q1 2017, up from 37 in Q4 2016.
- Funds reported $114M of Fate Therapeutics stock for Q1 2017, up 97% quarter-over-quarter.
- 24 funds opened new Fate Therapeutics positions in Q1 2017 and 4 closed out, a net change of +20 holders.
- The largest Fate Therapeutics buyer in Q1 2017 was EcoR1 Capital, an estimated $9.28M added.
- The largest Fate Therapeutics seller in Q1 2017 was BVF Inc, an estimated $6.64M sold.
Based on aggregated 13F filings for Q1 2017.